Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.44 |
| ▸ | CTSL | P07711 | 8/20 | 0.40 |
| ▸ | CTSB | P07858 | 7/20 | 0.40 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 5/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | CA7 | P43166 | 2/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27851332 | 1.00 | CTSS (0.44) | CTSSCTSLCTSBELOVL6L3MBTL1 | |
| SCHEMBL3802037 | 0.88 | CTSS (0.40) | CTSSCTSLCTSBELOVL6SMN1; SMN2 | |
| SCHEMBL3794151 | 0.88 | CTSS (0.40) | CTSSCTSLCTSBELOVL6SMN1; SMN2 | |
| SCHEMBL1139937 | 0.84 | ELOVL6 (0.42) | CTSSCTSLCTSBELOVL6FAAH | |
| SCHEMBL1139568 | 0.80 | CTSS (0.47) | CTSSCTSLCTSBELOVL6L3MBTL1 | |
| SCHEMBL12856053 | 0.80 | CTSS (0.49) | CTSSCTSLCTSB | |
| SCHEMBL12856054 | 0.80 | CTSS (0.49) | CTSSCTSLCTSB | |
| SCHEMBL1139250 | 0.80 | CTSS (0.60) | CTSSCTSLCTSB | |
| SCHEMBL1139248 | 0.80 | CTSS (0.60) | CTSSCTSLCTSB | |
| SCHEMBL1139819 | 0.77 | CTSS (0.44) | CTSSELOVL6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-7893099-B2 | Cyclopentane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | TBXA2R, ADORA1, CNR1 | CTSS 2367/4885CTSL 2122/4885CTSB 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.